Gossamer Bio (GOSS) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares.
View GOSS analyst ratings or view top-rated stocks.

10 equities research analysts have issued 1 year price objectives for Gossamer Bio's shares. Their GOSS share price forecasts range from $1.50 to $17.00. On average, they expect the company's share price to reach $7.32 in the next twelve months. This suggests a possible upside of 525.5% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.

Gossamer Bio's stock was trading at $2.17 at the beginning of 2023. Since then, GOSS shares have decreased by 46.1% and is now trading at $1.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our GOSS earnings forecast.

Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings data on Friday, March, 17th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.03.

WisdomTree BioRevolution Fund holds 2,078 shares of GOSS stock, representing 0.08% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.02%), Palo Alto Investors LP (3.63%), Platinum Investment Management Ltd. (2.48%), Acadian Asset Management LLC (2.32%), Two Sigma Investments LP (1.96%) and Two Sigma Advisers LP (1.93%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends.

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GOSS stock can currently be purchased for approximately $1.17.

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $111.67 million. The company earns $-229,380,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.

The company employs 185 workers across the globe.

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.